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Background: Tranexamic acid (TXA) is an antifibrinolytic drug used as a blood-sparing technique in many surgical
specialties. The principal objective of our meta-analysis was to review randomized, controlled trials (RCT) comparing
total blood loss and the number of patients receiving allogeneic blood transfusions with and without the use of
TXA for knee (TKA) and hip (THA) arthroplasty.
Methods: Studies were included if patients underwent primary unilateral TKA or THA; the study involved the
comparison of a TXA treatment group to a control group who received either a placebo or no treatment at all;
outcome measures included total blood loss TBL, number of patients receiving allogeneic blood transfusions, and/or
incidence of thromboembolic complications; the study was a published or unpublished RCT from 1995 – July 2012.
Results: Data were tested for publication bias and statistical heterogeneity. Combined weighted mean
differences in blood loss favoured TXA over control for TKA and THA patients respectively [ −1.149 (p < 0.001;
95% CI −1.298, -1.000), -0.504 (p < 0.001; 95% CI, -0.672, -0.336)]. Combined odds ratios favoured fewer patients
requiring allogeneic transfusions for TKA and THA with the use of TXA respectively [0.145 (p < 0.001; 95% CI,
0.094, 0.223), 0.327 (p < 0.001; 95% CI, 0.208, 0.515)]. Combined odds ratios indicated no increased incidence of
DVT with TXA use in TKA and THA respectively [1.030 (p = 0.946; 95% CI, 0.439, 2.420), 1.070 (p = 0.895; 95% CI,
0.393, 2.911)].
Conclusions: TXA should be considered for routine use in primary knee and hip arthroplasty to decrease blood loss.
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The prevalence of total knee (TKA) and total hip
arthroplasty (THA) is increasing and both are associated
with considerable blood loss [1-9] thereby increasing a
patient’s risk of transfusion [5,9,10]. Blood loss often
leads to significant postoperative anemia [11] predis-
posing to an increased risk for cardiopulmonary events,
transfusion reactions, and increased health care costs
[5,12]. Allogeneic transfusions may also increase the
patient’s risk for post-operative infection [3,10,13,14].
Tranexamic acid (TXA) is a synthetic amino acid
[2-4,6,9,12,14-16] which competitively blocks the lysine
binding sites on plasminogen and thereby slows the con-
version of plasminogen to plasmin [2,3,5-8,10,12,14-20].
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reproduction in any medium, provided the orin the surgical wound. TXA has been reported to reduce
blood loss and be cost effective in many areas of ortho-
pedic surgery, such as spinal surgery [11] as well as knee
and hip arthroplasty [15,17-19]. One significant concern
with TXA however, is the possibility that it, as well as other
antifibrinolytics, could increase the risk of developing
thromboembolic complications such as deep vein throm-
bosis (DVT).
We performed a meta-analysis of randomized, controlled
trials (RCT) to assess the efficacy of TXA in TKA and
THA for the outcomes of total blood loss (TBL), the
number of patients receiving allogeneic transfusions and
the incidence of DVT.
We hypothesized that the use of TXA in both TKA
and THA would significantly reduce blood loss and the
number of patients receiving allogeneic transfusions
without an increased incidence of DVT.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Eligibility criteria
Studies were included in the meta-analysis if: 1) patients
underwent primary unilateral TKA or THA; 2) the study
involved the comparison of a TXA treatment group to a
control group who received either a placebo or no treat-
ment at all; 3) outcome measures included TBL, number
of patients receiving allogeneic blood transfusions, and/
or incidence of thromboembolic complications; 4) the
study was a published or unpublished RCT from 1995 –
July 2012; 5) the procedure involved was not described
as ‘minimally invasive’ or ‘less invasive’. Both English
and non-English studies were included in the meta-
analysis. Data on cost-effectiveness was not included in
many research papers and thus was not used as an
eligibility criterion.
Study identification
Two independent reviewers completed a systematic
computerized search of online data-bases including
Pubmed, Ovid MEDLINE and EMBASE. The key words
used for the search included: tranexamic acid OR TXA
AND total knee replacement OR total hip replacement
OR total knee arthroplasty OR total hip arthroplasty OR
TKA OR THA OR TKR OR THR. We also searched
the Cochrane Database of Systematic Reviews, the
Cochrane Central Register of Controlled Trials and
www.Clinicaltrials.gov. After reviewing the title of the
study we retrieved the abstract if we felt it was appropri-
ate. We independently reviewed these abstracts and chose
those studies that were potentially relevant. Bibliographies
of each study included were reviewed for any further
studies. Further, we searched the archives of the American
Academy of Orthopedic Surgeons (2001–2011), Knee
Society (2001–2011), Canadian Orthopedic Association
(2003–2011), British Orthopedic Association (2002–2011)
meetings for other potential studies.
Assessment of study quality
All studies were reviewed by two independent reviewers
using the Jadad Score, a scale of 0 (very poor) to 5
(rigorous) was used to assess the methodological strength
of a clinical trial [21]. Any conflicts were resolved by con-
sensus. Studies with a Jadad score of 1 were considered
poor, scores of 2 were considered adequate and a score of
3 or higher was considered as high quality.
Data collection
The following data were collected from all manuscripts
for both the treatment group (TXA) as well as the control
group: patient demographics, number of patients, dose of
TXA, method of TXA administration, type of control
(saline, non-TXA), TBL and/or number of patients recei-
ving allogeneic transfusions, transfusion criteria, DVTscreening method, thromboprophylaxis used, incidence of
DVT and/or thromboembolic complications, as well as
cost effectiveness.
Statistical analysis
Knee and hip replacement data were analyzed separately
for our outcomes of interest: total surgical blood loss
and the number of patients requiring allogeneic blood
transfusions. In both cases, data were aggregated using a
random-effects model and the meta-analysis was perfor-
med using Comprehensive Meta-analysis version 2.0
(Engelwood, NJ).
The summary statistic used for the continuous out-
come of mean blood loss was the weighted mean differ-
ence (WMD). The WMD refers to the ratio of the
differences between the means of the treatment and
control groups divided by the standard deviation. In our
study, a negative WMD favored the treatment group
(TXA) and a positive WMD favored the control group.
Some studies did not provide standard deviation (SD)
values so, whenever possible, these values were cited
from a previous systematic review of antifibrinolytic
therapies by Kagoma et al. [22] which used pooled and
estimated SD values where studies had not provided
them. In some cases, if a CI was provided, the SD was
calculated using the following formula where U refers to
the upper limit of the CI, μ to the mean, s to the SD and
n to the number of study participants in each group
(TXC, control).
U μ ¼ s=sqrt nð Þ2
The summary statistic used for the outcomes: the
number of patients requiring allogeneic transfusions as
well as the incidence of DVT, was the odds ratio (OR).
In this case, the OR referred to the odds of a patient
requiring a blood transfusion in the treatment group
divided by the odds of a patient requiring a blood trans-
fusion in the control group; similarly, the odds of a
patient having a DVT in the treatment group divided by
the odds of a patient having a DVT in the control group.
An OR value of less than one indicates that fewer
patients in the TXA group required allogeneic blood
transfusions, or developed a DVT, than in the control
group. An OR value of greater than one indicates that
more patients in the TXA group required allogeneic blood
transfusions, or developed a DVT, than in the control
group. We used two strategies to assess statistical hetero-
geneity between studies for both of our outcome mea-
sures. First, we used the methods of Hedges and Olkin to
test for significance and homogeneity [23]. A p value < 0.1
was considered suggestive of statistical heterogeneity as
these tests are traditionally underpowered.
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using the I2 statistic. The I2 statistic is a measure of the
percentage of variation in the data that is as a result of
heterogeneity as opposed to chance. I2 values of 0-25%
are considered low, 25-75% are considered moderate
and over 75% are considered high heterogeneity. Pos-
sible sources of heterogeneity which we noted prior to
performing our study were: 1) the method of measuring/
calculating blood loss; 2) the dose of TXA and method
of administration; 3) the transfusion criteria 4) patient
diagnosis (osteoarthritis versus inflammatory arthritis).
In addition, two funnel-plots were constructed for the
outcomes of TBL and the number of patients requiring
allogeneic transfusions, in patients undergoing TKA, to
assess publication bias, the tendency of studies with a
negative result to not be published. The more asymme-
tric the funnel plot, the more potential bias.
Results
Using our search terms, a total of 420 references were
identified. Three hundred and eighty-two were excluded
after applying our eligibility criteria from their titles and/
or abstracts, including exclusion of duplicates. Of the
remaining 38 studies, three were excluded for lack of a
control group and one was not randomized. Therefore, a
total of 33 studies were included. All eligible studies
were English-language.
Out of the 33 studies, one was triple-blind [24], 24 were
double-blind [2,4-6,8,11,12,14,17,18,20,25-37], three were
single-blind [19,38,39], and in five studies the blinding was
unclear [3,40-44]. Additionally, 21 studies had a Jadad
score greater than three [2,4-6,11,12,14,17-19,24-27,31,
33-38] indicating they were of high quality. Ten studies
[2,3,6,18,24-26,31,35,36] used computer generated methods
of randomization, one study used random number tables/
lists [37] and 12 studies used sealed envelopes for allocation
concealment [5,6,11,12,17,24,25,27,29,38,40,41]. In eight
studies the randomization was performed by a person/
pharmacist/resident not involved in the study or the care of
patients [4,5,11,17,27,29,34,35]. In eight studies the method
of randomization was unclear [8,20,28,31,33,39,42,43]. Stu-
dy characteristics as well as patient characteristics can be
seen in Tables 1, 2, 3 and 4.
The methods of TXA administration varied between
studies. TXA was administered intravenously in 29
studies [2-6,8,12,14,17-20,25-36,38-42], intra-articularly
in three studies [24,37,43], orally in one study [35] and
topically in one study [11].
Figures 1 and 2 represent funnel plots examining for
potential publication bias between studies involving
patients undergoing TKA. Figure 1 reports the weighted
mean difference (WMD) of blood loss as a measure of the
treatment effect (TXA). Figure 2 reports the logs OR of
the numbers of patients requiring allogeneic transfusionsas a measure of the treatment effect. Figure 1 de-
monstrates only minimal asymmetry and a few outliers,
indicating mild publication bias. Figure 2 demonstrates
moderate asymmetry, also indicating mild publication
bias.
For TBL, the combined WMD for patients under-
going TKA was found to be −1.149 (p < 0.001; 95%
CI −1.298, -1.000) (Figure 3). This indicates that for
TKA patients, blood loss was less in the TXA groups in
comparison to the control group at a statistically signi-
ficant level. There was a high level of statistical hete-
rogeneity between studies (p = 0.000, I2 = 85.710). We
performed a sensitivity analysis here to explore causes of
heterogeneity. Pooling data from only those studies
administering TXA IV and calculating TBL based on the
weight change of surgical swabs and drapes as well as the
drain volume, demonstrated a statistically significant
benefit of TXA over control; WMD= −1.706 (p < .001
95% CI −1.949,-1.463).
The combined WMD value for TBL in THA was −0.504
(p < 0.001; 95% CI, -0.672, -0.336) (Figure 4). This indicates
that, for THA patients, blood loss was less in the TXA
groups in comparison to the control group at a statistically
significant level. There was a moderate level of heteroge-
neity between studies (p = 0.006, I2 = 58.000).
The combined OR for the number of patients receiving
allogeneic blood transfusions for patients undergoing
TKA was 0.145 (p < 0.001; 95% CI, 0.094, 0.223) (Figure 5).
This indicates that, for TKA patients, the number of
patients requiring allogeneic transfusions was less in the
TXA groups in comparison to the control group at a
statistically significant level. There was no heterogeneity
between studies (p =0.801, I2 = 0.000).
The combined OR for the number of patients receiving
allogeneic blood transfusions for patients undergoing
THA was 0.327 (p < 0.001; 95% CI, 0.208, 0.515) (Figure 6).
This indicates that, for THA patients, the number of
patients requiring allogeneic transfusions was less in the
TXA groups in comparison to the control group at a sta-
tistically significant level. There was moderate heterogen-
eity between studies (p = 0.135, I2 = 34.089).
The combined OR for the number of patients who
developed a DVT for patients undergoing TKA was 1.030
(p = 0.946; 95% CI, 0.439, 2.420) (Figure 7). This indicates
that, for TKA patients, there was no increase incidence of
DVT associated with the use of TXA. There was no
heterogeneity between studies (p =0.615, I2 = 0.000).
The combined OR for the number of patients who
developed a DVT for patients undergoing THA was
1.070 (p = 0.895; 95% CI, 0.393, 2.911) (Figure 8). This
indicates that, for THA patients, there was no increase
incidence of DVT associated with the use of TXA.
There was no heterogeneity between studies (p =0.677,
I2 = 0.000).
Table 1 Study characteristics - knee




Dose of TXA Method
of TXA
administration








Benoni, 1996 [17] 0 10 mg/kg 12 minutes prior to
tourniquet deflation + 3 hours later,
extra does for severe postoperative
bleeding.
IV S Hb < 85–100 g/L Swabs + drain None. Dalteparin sodium
n = 49, enoxaparin
n = 37
Hiippala, 1997 [12] 3 15 mg/kg prior to tourniquet
deflation + two additional 10 mg/kg
doses. 2nd dose 3–4 hours after 1st,
3rd 6–7 hours after 2nd.
IV S Hb < 100 g/L Swabs + drain Clinical exam +/−
venography.
Enoxaparin
Jansen, 1999 [2] 0 15 mg/kg 30 minutes prior to
surgery and every 8 hours for
3 days
IV S Post-op hemocrit <26% Swabs +
drapes + drain
Clinical exam. Fraxiparine.




Hb < 100 g/L N/R Clinical exam +/−
venography.
N/R
Ellis, 2001 [36] 0 15 mg/kg prior to tourniquet
deflation + 10 mg/kg/hr until
12 hrs after deflation.
IV Non-
TXA
Hemocrit < 27% N/R N/R Enoxaparin.
Tanaka, 2001 [41] 0 20 mg/kg 10 minutes before
surgery and/or 20 mg/kg
10 minutes prior to tourniquet
release.
IV S N/R Swabs + drain Venography 7–




Veien, 2002 [3] 0 10 mg/kg at end of surgery and
repeated three hours later. Max
dose = 1 g.




Good, 2003 [18] 4 10 mg/kg prior to tourniquet
release + three hours later.






Zohar, 2004 [35] 0 1)→ 15 mg/kg prior to tourniquet
release + 10 mg/kg/hr for
12 hours after release.
IV + O Non-
TXA





2)→ 15 mg/kg prior to tourniquet
release + 10 mg/kg/hr for 2 hours
after + 1 g TXA oral 6 + 12 hours after.
OR
3)→ 1 g TXA orally 1 hr before surgery +



















Table 1 Study characteristics - knee (Continued)
Orpen, 2006 [5] 0 15 mg/kg at time cement
mixing commenced.









1 10 mg/kg prior to tourniquet
deflation then + 3 hours later.








Álvarez, 2007 [6] 15 10 mg/kg + 1 mg/kg/hr perfusion. IV S Hb < 80 g/L or patients
showing signs/symptoms
of hypoxia
Drains Clinical exam. Bemiparin
Molloy, 2007 [19] 0 500 mg tranexamic acid five minutes








Kakar 2009 [4] 0 10 mg/kg prior to tourniquet deflation +
1 mg/kg/h until wound closure.
IV S Hb < 80 g/L or <10 g/L for




Wong, 2010 [11] 1 1.5 gm or 3 gm applied to joint for
5 min at end of surgery.












0 250 mg /25 mL injected after
fascial closure.
IA S When hemocrit < 25% Hb







Ishida, 2011 [43] 0 2000 mg/20 mL through
intra-articular drain.
IA S N/R Drains N/R Arteriovenous
impulse system for
24 hours surgery +
heparin sodium.
Roy, 2012 [37] 0 500 mg/5 mL through two
intra-articular drain.
IA S Hemocrit ≤28%; Drain
collection≥ 500 mL in 1st
8–10 hours + Hb loss































Table 2 Study characteristics - hip















Benoni, 2000 [29] 1 10 mg/kg at end of operation +
again three hours later.
IV S Clinical condition Swabs + drain Clinical exam. Klexane.
Benoni, 2001 [33] 2 10 mg/kg - max = 1 gram over
5–10 minutes, immediately before
operation started.
IV S Clinical decision.
Usually Hb
< 80–100 g/L.
Swabs + drain Clinical exam. Klexane.
Husted, 2003 [25] 0 10 mg/kg for 10 minutes, 15 minutes
prior to incision + 1 mg/kg/hr for
10 hours.













N/R Swabs + drain Clinical exam +
ascending phlebography.
None
Garneti, 2004 [14] 0 10 mg/kg. IV S N/R Swabs + drain Belfast scan, duplex




Lemay, 2004 [34] 1 Test dose 1 mL. 10 mg/kg prior
to surgery. 1 mg/kg/hr infusion
until wound closure.
IV S 90 g/L or 70 g/L –
dependant on patient.
Swabs + drain Clinical exam daily +
ultrasound of both inferior
limbs between post-op
days 5–10 or earlier if
symptoms present.
Dalteparin.





Niskanen, 2005 [30] 1 Three doses of 10 mg/kg. 1st over
5–10 minutes immediately before
operation. 2nd + 3rd, 8 hrs + 16 hours
after operation
IV S Hct 28% - 30% +
clinical situation
Swabs + drain Clinical exam +/−
ultrasound.
Dalteparin.
Claeys, 2007 [32] 0 15 mg/kg. IV S Hb < 85 g/L or
Hemocrit < 27%.




Kazemi, 2010 [8] 0 15 mg/kg slowly 5 minutes
pre-
operatively
IV S Used allowable blood
loss formula.
Swabs + drain Clinical exam. Enoxaparin.
Malhotra, 2011 [20] 0 15 mg/kg 15 minutes prior
to surgery.
IV S Reduction in Hb
exceeding 25% +
clinical symptoms.





McConnell, 2011 [38] 0 10 mg/kg bolus at start of surgery. IV Non-
TXA
N/R Change in hemocrit
method.
N/R Stockings + early
mobilization +
aspirin
Imai, 2012 [39] 1 g 1) 10 minutes prior to skin
closure 2) and again 2 hours later.
1 g 3) 10 minutes before surgery
4) and again 6 hours later.
IV Non-
TXA
N/R Change in hemocrit
method.
































Mean weight (kg) - TXA, C
(SD or Range)







TXA C TXA X TXA C TXA X TCA C TXA C
Hiippala, 1995 [27] 15 13 13 23 70 (56–82) 70 (63–78) 72 (10) 74 (10) 847 (356) 1549 (574) <0.001 10 12 N/R
Benoni, 1996 [17] 43 43 30 23 76 (7) 74 (7) 73 (14) 78 (16) 730 (280) 1410 (480) <0.001 8 24 <0.001
Hiippala, 1997 [12] 39 38 10 21 70 (7) 69 (5) 74 (13) 78 (12) 689 (289) 1509 (643) < 0.0001 17 34 <0.0001
Jansen, 1999 [2] 21 21 24 14 70.7 (62–80) 71.0 (64–84) 78.8 (11.0) 75.8 (12.4) 678 (352) 1419 (607) <0.001 2 13 <0.001
Engel, 2001 [42] 12 12 50 50 71 (9) 66 (11) 83 (12) 80 (13) 800 (295–1050) 865 (245–1370) N/R 0 3 N/R
Ellis, 2001 [36] 10 10 40 30 71 (5) 72 (8) 80 (12) 77 (15) N/R N/R N/R 1 7 N/R
Tanaka, 2001 [41] ** 73 26 29, 32, 30 65 (59–70), ,
65 (60–71),
65 (59–69)
65 (58–70) 60 (45–70),
60 (45–70),
60 (40–76)
61 (45 to 76) 720.4* (187.2) 1470 (264.8) N/R 17, 16, 14 26 N/R
Veien, 2002 [3] 15 15 73 93 70.5 (9.5) 69.5 (9.0) 78.7 (12.3) 74.3 (14.1) 409.7 (174.9) 761.7 (313.1) <0.001 0 2 N/R
Good, 2003 [18] 27 24 33 25 72 (46–83) 72 (50–84) 79 (13) 80 (13) 1045◊ (368.7 ) 1426◊ (620.9 ) <0.001 3 14 <0.001
Zohar, 2004 [35] *** 60 20 30, 20, 40 35 73 (8), 69 (7),
69 (10)
73 (7) 78 (12), 75 (13),
77 (13)
75 (12) N/R N/R N/R 3, 2, 4 12 N/R








660 (317.6)† 726 (333.0) † 0.55 1 3 N/R
Camarasa, 2006 [31] 35 60 26 20 73 (61–84) 72 (52–85) N/R 1095 (473) 1784 (660) N/R N/R N/R
Álvarez, 2007 [6] 46 49 15 20 71 (9) 72 (7) N/R 1301 (621) 1744 (804) 0.002 N/R N/R
Molloy, 2007 [19] 50 50 N/R N/R N/R N/R N/R 1225 (499) 1415 (416) 0.041 5 11 0.79
Kakar 2009 [4]‡ 12 12 25 33 62.4 (9.4), 66.2 (4.8) 67.9 (10.8) 63.4 (7.2) 160 (87) 270 (88) <0.05 N/R N/R
Wong, 2010 [11] □ 64 35 19, 42 □ 37 67 (11.9),
63.9 (10.6)
68.4 (10.4) 82.0 (15.6),
81.8 (14.7)
87.9 (19.2) 1295 (353.7), 1208
(376.0)
1610 (378.6) 0.0001 1, 0 2 0.083
Ishida, 2011 [43] 50 50 12 12 73.3 (5.0) 73.5 (6.1) 59.7 (9.0) 59.7 (10.1) N/R N/R 0 1 N/R
Sa-ngasoongsong,
2011 [24]
24 24 78 82 69.0 (8.2) 69.2 (7.6) N/R N/R 206.3 (115.4) 385.1 (145.2) <0.0001° 1 8 0.023
Roy, 2012 [37] 25 25 40 36 66.04 (7.15) 66.56 (8.03) N/R N/R **** 109.6 ± 71.54 +
401 ± 82.44
**** 194 ± 79.66 + 870
± 201.04
N/R 2 7 Not
Significant
* - Weighted Mean Value7, † - Calculated from 95% CI, § Average, SD – Standard Deviation, C – Control group, TXA – Tranexamic acid group, ◊ - Median Value, DVT – deep venous thrombosis, ** (Patients received
pre-op TXA, patients received intra-op TXA, patients received both pre + intra op TXA), ‡ - Unilateral TKA data reported only, □ - (Patients received 1.5 gm TXA, patients received 3 gm TXA), *** (Patients received TXA
bolus + long IV, patients received TXA bolus + short IV, patients received oral TXA), N/R – not reported. **** Sum of per-operative and drain collection. ↑Patients received TXA prior to tourniquet deflation, an additional



















Table 4 Patient characteristics - hip






Mean age TXA,C (SD or
range)
Mean weight (kg) – TXA, C
(SD or Range)




TXA C TXA C TXA C TXA C TXA C TXA C
Ekbäck, 2000 [28] 20 20 45 55 66.4 (9.0) 65.6 (8.8) 81.1 (13) 76.8 (13) 1130 (400) 1770 (523) <0.001 5 5 N/R
Benoni, 2000 [29] 20 19 30 58 69.5 (10) 68 (10) 76 (14), 77 (11) 990 ◊(210 ), 950 ◊(162.5) N/R 45 79 0.05
Benoni, 2001 [33] 18 20 50 50 66 (9.5) 68 (9.4) 79 (16) 78 (17) 759 (275.8†) 996 (398†) 0.03 22 40 0.2
Husted, 2003 [25] 20 20 35 30 65 67 N/R 814 (1323.8†) 1231 (1692.7†) 0.001 10 35 0.04
Yamasaki, 2004 [41] 20 20 95 90 55.5 (14.2) 61.2 (6.9) 52.6 (11.5) 54.5 (8.7) 1350 (477) 1667 (401) <0.05 0 0 N/R
Garneti, 2004 [14] 25 25 N/R 69.6 (11.99) 67.6 (11.4) N/R 1443 (809) 1340 (665) 0.822 64 56 N/R
Lemay, 2004 [34] 20 19 60 68 59.7 (10.3) 53.6 (12.8) 80.1 (15.7) 74.7 (14.1) 1308 (462) 1469 (405) N/R 0 42 0.0012
Johansson, 2005 [26] 47 53 53 53 69 (7) 69 (7) 81 (16) 78 (13) 969 (434) 1324 (577) <0.001 17 43 0.009
Niskanen, 2005 [30] 19 20 32 35 66 (9.1) 65 (8.2) 80 (19) 82 (14) 792 (390.1†) 1102 (485.2 †) 0.03 26 40 0.3
Claeys, 2007 [32] 20 20 25 35 73 (8) 68 (11) 76 (15) 72 (16) 801 (244) 1038 (289) 0.013 5 30 <0.05
Kazemi, 2010 [8] 32 32 72 63 46.6 (16.2) 45.4 (17.2) 72.1 (10.4), 69.9 (11.1) 1024 (544) 1399 (587) 0.024 N/R N/R
Malhotra, 2011 [20] 25 25 40 48 52.6 (39–72) 54.7 (40–71) 80.2 (58–100) 81.9 (62–98) 410 (300–510) –
range
615 (515–750) –range <0.5 24 72 N/R
McConnell, 2011 [38] 22 22 32 41 N/R N/R N/R N/R 930 (399†) 1200 (469†) 0.02 0 0 N/R












56.3 (47–80) 649, 566,
388, 418**
1026** N/R 0 0 N/R
◊Sum of perioperative and drain medians7, † - Calculated from 95% CI, C – Control group, TXA – Tranexamic group, SD – Standard Deviation, DVT – deep venous thrombosis, N/R – not reported. *Patients received 1 g




































Weighted Difference in Means 
Figure 1 Funnel plot of standard error by weighted difference in means.
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http://www.biomedcentral.com/1756-0500/6/184In regards to complications, overall, a total of 30 DVT,
three pulmonary embolisms (PE), one myocardial infarc-
tion (patient had a history of ischaemic heart disease
[27]), three wound infections, nine wound hematomas,
one chest infection were reported in the TXA groups. In
the control groups a total of 20 DVT, four PE, five
wound infections and six wound hematomas were
reported.
Discussion
The results of our meta-analysis demonstrate a statisti-
cally significant benefit for TXA in reducing TBL and
the number of patients receiving allogeneic transfusions

















Figure 2 Funnel plot of standard error by log odds ratio.for TKA patients. There were also minimal differences
in the incidence of thromboembolic complications with
the use of TXA in our review.
In addition to TXA, other antifibrinolytic drugs, such
as aprotinin, epsilon aminocaproic acid (EACA) , and
fibrin spray have been used to decrease surgical blood
loss [22]. Aprotinin however may cause allergic reactions
[13,31], thrombosis, nephrotoxicity as well as spongi-
form encephalopathy [13] and has not been shown to be
cost-effective [31]. Aminocaproic acid has been shown
be more costly and yet less effective than TXA [13]
(TXA is 7–10 times as potent [28]). TXA has also been
shown to be less expensive when compared to fibrin
sealants and just as effective [11,15].0 1 2 3 4
dds ratio
Study name Subgroup within study Year Statistics for each study
Lower Upper 
limit limit p-Value
Hiippala. et al. knees 1995 -1.496 -2.335 -0.656 0.000
Benoni et al. knees 1996 -1.731 -2.226 -1.235 0.000
Hiippala et al. knees 1997 -1.652 -2.170 -1.135 0.000
Jansen et al. knees 1999 -1.493 -2.177 -0.809 0.000
Tanaka et al. knees 2001 -3.570 -4.239 -2.901 0.000
Veien et al. knees 2002 -1.388 -2.185 -0.591 0.001
Good et al. knees 2003 -0.757 -1.326 -0.188 0.009
Orpen et al. knees 2006 -0.203 -0.933 0.527 0.586
Camarasa et al. knees 2006 -1.151 -1.599 -0.703 0.000
Molloy et al. knees 2007 -0.414 -0.810 -0.017 0.041
Alvarez et al. knees 2007 -0.614 -1.026 -0.202 0.003
Kakar et al. knees 2009 -1.257 -2.133 -0.381 0.005
Wong et al. knees 2010 -0.858 -1.363 -0.353 0.001
Sa-ngasoongsong et al. knees 2011 -1.363 -1.991 -0.735 0.000
-1.149 -1.298 -1.000 0.000
-2.00 -1.00 0.00 1.00 2.00
Favours TXA Favours Control
Wtd. Diff in means and 95% CI
WMD
Figure 3 Forest plot of combined WMD values for total blood loss in knee arthroplasty.
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http://www.biomedcentral.com/1756-0500/6/184In a fiscally constrained health care system, the cost
benefit analysis of a therapeutic intervention is critical.
Benoni et al. [17] and Good et al. [18] described total
cost savings of 11, 354 SEK and £1100 respectively for
patients undergoing TKA using TXA. Molloy et al. also
noted an incremental cost per patient in their TXA
group of only £4, compared to £380 in their fibrin spray
group [19]. In their THA cohort, Benoni et al. [33] de-
scribed a total savings of £625 per patient using TXA.
Some have estimated a yearly savings of $65,000.00
(Can) for 1000 primary arthroplasties with routine TXAStudy name Subgroup within study Year Statistics for each st
Lower Upper 
limit limit
Ekback et al. hips 2000 -1.375 -2.064 -0.686
Benoni. et al. hips 2000 0.212 -0.417 0.842
Benoni et al. hips 2001 -0.686 -1.341 -0.030
Husted et al. hips 2003 0.274 -0.348 0.897
Yamasaki et al. hips 2004 -0.719 -1.359 -0.080
Lemay et al. hips 2004 -0.370 -1.003 0.263
Garneti et al. hips 2004 0.139 -0.416 0.694
Johansson et al. hips 2005 -0.690 -1.094 -0.285
Niskanen et al. hips 2005 -0.702 -1.349 -0.055
Claeys et al. hips 2007 -0.886 -1.536 -0.237
Kazemi et al. hips 2010 -0.663 -1.166 -0.159
McConnell et al. hips 2011 -0.620 -1.225 -0.015
-0.504 -0.672 -0.336
WMD
Figure 4 Forest plot of combined WMD values for total blood loss inuse [15]. The role of TXA use in routine primary
arthroplasty appears cost effective but should be an
outcome measure routinely studied in RCTs.
A single adequately powered RCT to detect a 0.5SD
effect size difference in TBL (assuming 80% power and
an alpha error rate of 5%) would require 63 patients per
arm. By this calculation, all of the individual studies
included in our meta-analysis were underpowered, sug-
gesting that those concluding no difference between
groups committed a type II beta error. This highlights















-2.00 -1.00 0.00 1.00 2.00
Favours TXA Favours Control
Wtd. Diff in means and 95% CI
hip arthroplasty.
Study name Subgroup within study Time point Statistics for each study Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit p-Value
Hiippala. et al. knees 1995 0.167 0.017 1.671 0.128
Benoni et al. knees 1996 0.181 0.068 0.480 0.001
Hiippala et al. knees 1997 0.091 0.027 0.306 0.000
Jansen et al. knees 1999 0.065 0.012 0.355 0.002
Tanaka et al. knees 2001 0.020 0.001 0.366 0.008
Engel et al. knees 2001 0.109 0.005 2.365 0.158
Ellis et al. knees 2001 0.048 0.004 0.563 0.016
Veien et al. knees 2002 0.174 0.008 3.956 0.273
Good et al. knees 2003 0.089 0.021 0.380 0.001
Zohar et al. knees 2004 0.074 0.013 0.411 0.003
Orpen et al. knees 2006 0.262 0.024 2.878 0.273
Molloy et al. knees 2007 0.394 0.126 1.233 0.109
Wong et al. knees 2010 0.550 0.047 6.379 0.633
Ishida et al. knees 2011 0.327 0.013 8.215 0.497
Sa-ngasoongsong et al. knees 2011 0.087 0.010 0.765 0.028
Roy et al. knees 2012 0.224 0.041 1.210 0.082
0.145 0.094 0.223 0.000
0.01 0.1 1 10 100
Favours TXA Favours Control
Figure 5 Forest plot of combined OR values for the number of patients requiring allogeneic transfusions in knee arthroplasty studies.
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http://www.biomedcentral.com/1756-0500/6/184as our study reviewed 33 manuscripts including a total
of 1,957 patients, thereby increasing the power of our
conclusion.
Additional meta-analyses and systematic reviews ana-
lyzing the efficacy of TXA in TKA and THA have been
published. Zufferey et al. [44] and Kagoma et al. [22]
examined the efficacy of TXA, aprontinin and EACA.
However, data were pooled for orthopaedic procedures
and antifibrinolytic treatment respectively. Zhang et al.
[45] and Yang et al. [46] published meta-analyses analyz-
ing blood loss, transfusion rates and rates of DVT with
TXA in TKA. Data from bilateral TKAs were included,Study name Subgroup within study Time point Statistics for each
Odds Lower Upper
ratio limit limit
Ekback et al. hips 2000 1.000 0.058 17.181
Benoni. et al. hips 2000 0.218 0.053 0.895
Benoni et al. hips 2001 0.429 0.103 1.785
Husted et al. hips 2003 0.206 0.037 1.159
Lemay et al. hips 2004 0.033 0.002 0.626
Garneti et al. hips 2004 1.397 0.449 4.350
Johansson et al. hips 2005 0.268 0.105 0.681
Niskanen et al. hips 2005 0.536 0.138 2.082
Claeys et al. hips 2007 0.123 0.013 1.138
Malhotra et al. hips 2011 0.123 0.035 0.436
0.327 0.208 0.515
Figure 6 Forest plot of combined OR values for the number of patienpotentially leading the significant heterogeneity in mean
differences of total blood loss. Cid and Lozano [47]
examined transfusion rates in TKA with TXA however
only included nine studies. Ho and Ismail [48] studied
the effect of TXA with respect to transfusion rates. The
majority of studies were for TKAs and sample size was
fewer than 10 studies. Two systematic reviews and
meta-analyses of TXA in TKA and THA were published
in 2011 by Alshryda et al. [49] and Sukeik et al. [50]
respectively. These reviews investigated the effects of
TXA in TKA and THA with respect to total blood loss,
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ts requiring allogeneic transfusions in hip arthroplasty studies.
Study name Subgroup within study Time point Statistics for each study Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit p-Value
Hiippala. et al. knees 1995 0.148 0.006 3.397 0.232
Benoni et al. knees 1996 1.368 0.287 6.512 0.694
Hiippala et al. knees 1997 0.973 0.130 7.283 0.979
Jansen et al. knees 1999 0.181 0.008 4.017 0.280
Engel et al. knees 2001 5.952 0.256 138.249 0.266
Good et al. knees 2003 0.880 0.114 6.781 0.902
Wong et al. knees 2010 2.345 0.202 27.201 0.496
1.030 0.439 2.420 0.946
0.01 0.1 1 10 100
Favours TXA Favours Control
Figure 7 Forest plot of combined OR values for the number of patients who developed a DVT in knee arthroplasty studies.
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http://www.biomedcentral.com/1756-0500/6/184Both, however, included fewer than ten studies in their
analysis of total blood loss. Furthermore, Alshryda et al.
included fewer than 15 studies in their analysis of
allogeneic transfusions, and Sukeik et al. included fewer
than 10. Despite their differences, all reviews came to
conclusions analogous to our own.
There were several strengths of our review and meta-
analysis. First, we performed exhaustive searches of the
English and non-English languages literature to limit
publication bias and pooled data from 33 manuscripts,
including only RCTs. Second, many of our studies had
Jadad scores of greater than three, indicating that most
articles were of high quality.
Limitations
Our paper also has limitations. We used the Jadad score
for assessing the quality of the individual studies. We
recognize that this tool has limitations. It has been
described as simplistic as it takes into account a limited
number of variables and does not take into considerationStudy name Subgroup within study Time point Statistics for each
Odds Lower Upper
ratio limit limit
Ekback et al. hips 2000 1.000 0.058 17.18
Benoni. et al. hips 2000 0.941 0.165 5.36
Claeys et al. hips 2007 8.200 0.396 169.89
Kazemi et al. hips 2010 0.323 0.013 8.23
Imai et al. hips 2012 0.905 0.163 5.03
1.070 0.393 2.91
Figure 8 Forest plot of combined OR values for the number of patienbias as a result of allocation concealment [51]. In our
study, we cannot exclude the presence of additional
unpublished trials that showed a negative or an equivocal
difference between the intervention and control groups.
We note as well some limitations related to heterogeneity.
We found moderate heterogeneity between TKA studies
reporting blood loss however we performed a sensitivity
analysis here to explore the cause of this heterogeneity.
Despite differences among the studies, our findings
suggest that across the various methods of measuring
TBL or routes of administration, TXA lead to decreased
blood loss as compared with alternative approaches. We
have presented the I2 value for each outcome measure
analyzed. Please note we present the data despite some
with high heterogeneity and suggest that the reader use
caution in interpreting the results.
Conclusion
In conclusion, we find that TXA leads to a statistically
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http://www.biomedcentral.com/1756-0500/6/184allogeneic transfusions, with no apparent increased risk of
thromboembolic complications. Incomplete reporting of
complications prevented us from pooling of this data and
such larger trials are still needed to confirm the safety of
TXA use in routine primary TKA and THA.
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